KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Retained Earnings (2009 - 2026)

Johnson & Johnson recorded quarterly Retained Earnings of -$14.8 billion in Q1 2026, down 108.78% quarter-over-quarter from $169.0 billion in Q4 2025, and down 109.12% year-over-year from $162.6 billion in Q1 2025.

Johnson & Johnson's Retained Earnings history runs 18 years deep, the most recent figure standing at -$14.8 billion for Q1 2026.

  • In Q1 2026, Retained Earnings fell 109.12% year-over-year to -$14.8 billion; the TTM figure through Mar 2026 stood at -$14.8 billion (down 109.12% YoY), while the FY2025 annual figure was $169.0 billion, up 8.46% from the prior year.
  • Retained Earnings came in at -$14.8 billion for Q1 2026 at Johnson & Johnson, down from $169.0 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $169.0 billion in Q4 2025 to a low of -$15.3 billion in Q4 2022.
  • A 5-year average of $65.4 billion and a median of $56.6 billion in 2022 frame the typical range for Retained Earnings.
  • Across the five-year window, Retained Earnings slumped 111.52% in 2022 and jumped 1343.64% in 2024, its largest moves.
  • Johnson & Johnson's Retained Earnings stood at -$15.3 billion in 2022, then rose by 18.08% to -$12.5 billion in 2023, then surged by 1343.64% to $155.8 billion in 2024, then climbed by 8.46% to $169.0 billion in 2025, then sank by 108.78% to -$14.8 billion in 2026.
  • According to Business Quant data, Retained Earnings over the past three periods registered -$14.8 billion, $169.0 billion, and -$15.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Retained Earnings (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 29.51 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -14.83 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -17.87 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 66.72 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -190.00 Mn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 78.00 Mn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -7.20 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -1.37 Bn
10 Gsk 88.34 Bn 83.66 Bn - 1.76 Bn

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 -14.83 Bn
Dec 28, 2025 168.98 Bn
Sep 28, 2025 -15.24 Bn
Jun 29, 2025 -14.31 Bn
Mar 30, 2025 162.64 Bn
Dec 29, 2024 155.79 Bn
Sep 29, 2024 -12.52 Bn
Jun 30, 2024 -11.25 Bn
Mar 31, 2024 153.38 Bn
Dec 31, 2023 -12.53 Bn
Oct 1, 2023 152.54 Bn
Jul 2, 2023 129.38 Bn
Apr 2, 2023 124.56 Bn
Jan 1, 2023 128.35 Bn
Oct 2, 2022 -15.29 Bn
Jul 3, 2022 -13.84 Bn
Apr 3, 2022 124.38 Bn
Jan 2, 2022 -13.06 Bn
Oct 3, 2021 -15.42 Bn
Jul 4, 2021 120.15 Bn
Apr 4, 2021 116.51 Bn
Jan 3, 2021 113.89 Bn
Sep 27, 2020 114.83 Bn
Jun 28, 2020 113.90 Bn
Mar 29, 2020 -16.24 Bn
Dec 29, 2019 110.66 Bn
Sep 29, 2019 -15.53 Bn
Jun 30, 2019 -14.97 Bn
Mar 31, 2019 -15.52 Bn
Dec 30, 2018 106.22 Bn
Sep 30, 2018 107.62 Bn
Jul 1, 2018 -14.78 Bn
Apr 1, 2018 104.34 Bn
Dec 31, 2017 101.79 Bn
Oct 1, 2017 -12.75 Bn
Jul 2, 2017 113.21 Bn
Apr 2, 2017 111.64 Bn
Jan 1, 2017 110.55 Bn
Oct 2, 2016 -12.72 Bn
Jul 3, 2016 106.74 Bn
Apr 3, 2016 -12.39 Bn
Jan 3, 2016 -13.17 Bn
Sep 27, 2015 -12.86 Bn
Jun 28, 2015 -12.05 Bn
Mar 29, 2015 98.66 Bn
Dec 28, 2014 -10.72 Bn
Sep 28, 2014 96.56 Bn
Jun 29, 2014 93.75 Bn
Mar 30, 2014 -2.65 Bn
Dec 29, 2013 -2.86 Bn
Sep 29, 2013 87.70 Bn
Jun 30, 2013 -6.81 Bn
Mar 31, 2013 -6.69 Bn
Dec 30, 2012 -5.81 Bn
Sep 30, 2012 -4.93 Bn
Jul 1, 2012 83.53 Bn
Apr 1, 2012 83.10 Bn
Jan 1, 2012 -5.63 Bn
Oct 2, 2011 -3.07 Bn
Jul 3, 2011 -1.19 Bn
Apr 3, 2011 -2.02 Bn
Jan 2, 2011 -3.53 Bn
Oct 3, 2010 -2.92 Bn
Jul 4, 2010 -5.71 Bn
Apr 4, 2010 73.18 Bn
Jan 3, 2010 -3.06 Bn
Sep 27, 2009 -2.66 Bn
Jun 28, 2009 -4.48 Bn